TVAX Biomedical, a biotech company focused on cancer cell vacination and T cell cancer treatment, withdrew its plans for an initial public offering on Thursday, citing poor market conditions. The Lenexa, KS-based company was founded in 2004 and was looking to raise $20 million to fund clinical trials for its product candidate, TVI-Brain-1. Roth Capital was set to be the sole bookrunner on the deal.
